Editorial: Single-domain antibodies—biology, engineering and emerging applications, volume II
2024
Single-domain antibodies: biology, engineering, and applications
Editorial
Author Information
Author(s): Henry Kevin A., Hussack Greg, Gettemans Jan, Brooks Cory L.
Primary Institution: Human Health Therapeutics Research Centre, National Research Council Canada
Conclusion
Single-domain antibodies (sdAbs) have evolved significantly and are now recognized as a distinct class of binding molecules with various applications in medicine.
Supporting Evidence
- The first sdAb-based drug was approved in 2018 for treating a blood disorder.
- sdAbs have shown effectiveness against SARS-CoV-2, especially in well-designed molecules.
- Recent approvals of sdAb-based therapies highlight their growing importance in medicine.
Takeaway
Single-domain antibodies are special types of antibodies that are getting better and better at helping doctors find and treat diseases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website